M Bialer

Summary

Affiliation: The Hebrew University
Country: Israel

Publications

  1. ncbi request reprint Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine
    M Bialer
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
    Epilepsy Res 32:371-8. 1998
  2. ncbi request reprint Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
    M Bialer
    School of Pharmacy and David R Bloom Centre for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
    Epilepsy Res 34:1-41. 1999
  3. ncbi request reprint Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs
    M Bialer
    Department of Pharmaceutics, and David R Bloome Centre for Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P O Box 12065, Jerusalem, Israel
    J Control Release 62:187-92. 1999
  4. ncbi request reprint Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
    M Bialer
    School of Pharmacy and David R Bloom Centre for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, Israel
    Epilepsy Res 43:11-58. 2001
  5. ncbi request reprint Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid
    O Spiegelstein
    Department of Pharmaceutics, The Hebrew University of Jerusalem, Israel
    Pharm Res 16:1582-8. 1999
  6. ncbi request reprint Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
    M Bialer
    School of Pharmacy and David R Bloom Centre for Pharmacy, Faculty of Medicine, Ein Karem, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
    Epilepsy Res 51:31-71. 2002
  7. ncbi request reprint Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug
    N Isoherranen
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
    Epilepsia 42:831-6. 2001
  8. ncbi request reprint Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity
    A Haj-Yehia
    Department of Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Israel
    Pharm Res 6:683-9. 1989
  9. ncbi request reprint Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
    N Isoherranen
    Department of Pharmaceutics and Medicinal Chemistry and Natural Products, The Hebrew University of Jerusalem, Jerusalem, Israel
    Epilepsia 42:825-30. 2001
  10. ncbi request reprint Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxypropyl valpromide, a central nervous system--active chiral valproylamide
    M Wasserman
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Israel
    Ther Drug Monit 23:414-20. 2001

Collaborators

  • Rene Levy
  • E Perucca
  • H S White
  • H Nau
  • R H Finnell
  • Adrian Harwood
  • B Yagen
  • S Eyal
  • N Isoherranen
  • O Spiegelstein
  • G S J Mannens
  • J A Shimshoni
  • M Wasserman
  • M Roeder
  • V Schurig
  • W Meuldermans
  • C G M Janssen
  • J Hendrickx
  • E C Dalton
  • M Kao
  • R S B Williams
  • S Chien
  • T Verhaeghe
  • M Bockx
  • A Jenkins
  • M F Kelley
  • K Ewan
  • B Verreet
  • B Van Hoof
  • I Goris
  • N Pessah
  • E Fibach
  • J G Lamb
  • Y Altschuler
  • M Smith-Yockman
  • J H Woodhead
  • S Blotnik
  • N Papo
  • S Soback
  • G D Bennett
  • M Radatz
  • A Haj-Yehia

Detail Information

Publications15

  1. ncbi request reprint Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine
    M Bialer
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
    Epilepsy Res 32:371-8. 1998
    ....
  2. ncbi request reprint Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
    M Bialer
    School of Pharmacy and David R Bloom Centre for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
    Epilepsy Res 34:1-41. 1999
    ..This paper summarizes the presentations made at the conference...
  3. ncbi request reprint Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs
    M Bialer
    Department of Pharmaceutics, and David R Bloome Centre for Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P O Box 12065, Jerusalem, Israel
    J Control Release 62:187-92. 1999
    ..VGD is mainly metabolized to N-valproyl glycine by a nonoxidative hydrolytic metabolic pathway. It did not operate as chemical drug delivery systems of VPA and glycine or GABA, but acted rather as a drug on its own...
  4. ncbi request reprint Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
    M Bialer
    School of Pharmacy and David R Bloom Centre for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, Israel
    Epilepsy Res 43:11-58. 2001
    ..Finally, updates on felbamate, fosphenytoin, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide, and the antiepileptic vagal stimulator device are presented...
  5. ncbi request reprint Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid
    O Spiegelstein
    Department of Pharmaceutics, The Hebrew University of Jerusalem, Israel
    Pharm Res 16:1582-8. 1999
    ....
  6. ncbi request reprint Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
    M Bialer
    School of Pharmacy and David R Bloom Centre for Pharmacy, Faculty of Medicine, Ein Karem, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
    Epilepsy Res 51:31-71. 2002
    ..Updates on fosphenytoin, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin, zonisamide, new formulations of valproic acid, and the antiepileptic vagal stimulator device are also presented...
  7. ncbi request reprint Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug
    N Isoherranen
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
    Epilepsia 42:831-6. 2001
    ..CONCLUSIONS: The results obtained in this study suggest that VGD has a broad spectrum of anticonvulsant activity and promising potential as a new AED...
  8. ncbi request reprint Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity
    A Haj-Yehia
    Department of Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Israel
    Pharm Res 6:683-9. 1989
    ..This amide-acid biotransformation appeared to be dependent upon the chemical structure, especially upon the substitution at position beta of the molecule...
  9. ncbi request reprint Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
    N Isoherranen
    Department of Pharmaceutics and Medicinal Chemistry and Natural Products, The Hebrew University of Jerusalem, Jerusalem, Israel
    Epilepsia 42:825-30. 2001
    ..Because REV has more favorable PK in dogs than LEV, the higher antiepileptic potency of LEV is more likely due to intrinsic pharmacodynamic activity rather than to enantioselective PK...
  10. ncbi request reprint Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxypropyl valpromide, a central nervous system--active chiral valproylamide
    M Wasserman
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Israel
    Ther Drug Monit 23:414-20. 2001
    ..This is the first report of significant stereoselectivity in the anticonvulsant activity of a valproylamide with a chiral carbon situated on the alkyl chain of the amine moiety...
  11. ncbi request reprint The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior
    J A Shimshoni
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Karem, P O Box 12065, Jerusalem 91120, Israel
    Mol Pharmacol 71:884-92. 2007
    ..These results suggest a route to a new generation of central nervous system-active VPA analogs that specifically target bipolar disorder...
  12. ncbi request reprint Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid
    O Spiegelstein
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
    Chirality 11:645-50. 1999
    ..Due to its better anticonvulsant activity than VPA and lack of teratogenicity, PID (in a stereospecific or racemic form) has the potential to become a new antiepileptic and CNS drug...
  13. pmc The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver
    S Eyal
    Department of Pharmaceutics, Faculty of Medicine, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
    Br J Pharmacol 149:250-60. 2006
    ..In this study we assessed whether valproic acid induces P-gp function in tumour cells. We also investigated effects of valproic acid on the mRNA for P-gp and the cytochrome P450, CYP3A, in rat livers...
  14. ncbi request reprint [Interactions of antiepileptic drugs]
    M Bialer
    Zh Nevrol Psikhiatr Im S S Korsakova 105:59-60. 2005
  15. ncbi request reprint The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans
    G S J Mannens
    Department of Preclinical Pharmacokinetics, Johnson and Johnson Pharmaceutical Research and Development, A Division of Janssen Pharmaceutica N V, Turnhoutseweg 30, B 2340 Beerse, Belgium
    Drug Metab Dispos 35:554-65. 2007
    ..In conclusion, the disposition of RWJ-333369 in humans is characterized by virtually complete absorption, extensive metabolism, and unchanged drug as the only significant circulating species...